Valmont Records Longest BVLOS Drone Flight on the Wings of T-Mobile 5G
The Un-carrier helps Valmont capture mission-critical data in industry-first beyond visual line of sight (BVLOS)…
News
Oxurion Announces Results of the Extraordinary Shareholders’ Meeting of 22 May 2023
Regulated Information Leuven, Belgium, Boston, MA, US – June 5, 2023 – 07.00 PM CET – Oxurion NV (Euronext…
The Snowflake Ecosystem Will Converge at the World’s Largest Data, Apps, and AI Event, Snowflake Summit 2023
Snowflake’s fifth annual user conference will reveal how enterprises can bring generative AI to their…
Pharmatech Associates’ Board of Directors Appoints Sireesha Yadlapalli as Chief Executive Officer
HAYWARD, Calif.–(BUSINESS WIRE)–#BigPharma—The Board of Directors of Pharmatech Associates today announced the appointment of Sireesha…
APQC Recognizes Eight Organizations for Excellence in Knowledge Management
HOUSTON–(BUSINESS WIRE)–APQC, the benchmarking and best practices research firm, has named eight organizations as recipients…
Mercedes-Benz Financial Services Announces In-Car Payment Feature for Parking, powered by Mercedes pay, at AutoTech Detroit
Introduces Hassle Free, Time-saving, In-Car Parking Payments Using Parkopedia’s Nationwide Live Parking Database FARMINGTON HILLS,…
Mithra – Publication of a transparency notification received from Scorpiaux BV
Publication of a transparency notification received from Scorpiaux BV Liege, Belgium, 05 June 2023 –…
Mithra – Publication of a transparency notification received from Scorpiaux BV
Publication of a transparency notification received from Scorpiaux BV Liege, Belgium, 05 June 2023 –…
CARVYKTI®▼ (ciltacabtagene autoleucel; cilta-cel) Reduces Risk of Disease Progression or Death by 74 Percent in Earlier-Line Multiple Myeloma Treatment in the Landmark Phase 3 CARTITUDE-4 Study
At 16 months median follow-up, cilta-cel significantly improved progression-free survival compared to two standard of…
CARVYKTI®▼ (ciltacabtagene autoleucel; cilta-cel) Reduces Risk of Disease Progression or Death by 74 Percent in Earlier-Line Multiple Myeloma Treatment in the Landmark Phase 3 CARTITUDE-4 Study
At 16 months median follow-up, cilta-cel significantly improved progression-free survival compared to two standard of…
Innovation Pharma Announces BeaMed Technologies Breakthrough in Development of Fiber Optic Probes for StingRay Laser System; Paves Way for Groundbreaking Integration Testing
WAKEFIELD, MA, June 05, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – Innovation Pharmaceuticals (OTCQB:IPIX) (“the…
Innovation Pharma Announces BeaMed Technologies Breakthrough in Development of Fiber Optic Probes for StingRay Laser System; Paves Way for Groundbreaking Integration Testing
WAKEFIELD, MA, June 05, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – Innovation Pharmaceuticals (OTCQB:IPIX) (“the…
Tiziana Life Sciences Announces Reduction in Microglial Activation in a Total of 5 Out of 6 Intranasal Foralumab Expanded Access Patients with Non-Active Secondary Progressive Multiple Sclerosis
Figure 1 Baseline versus 3-month PET scans Results confirm positive signal previously reported in the…
Tiziana Life Sciences Announces Reduction in Microglial Activation in a Total of 5 Out of 6 Intranasal Foralumab Expanded Access Patients with Non-Active Secondary Progressive Multiple Sclerosis
Figure 1 Baseline versus 3-month PET scans Results confirm positive signal previously reported in the…
Defender Pharmaceuticals Reports Positive Results from Pivotal Phase III Clinical Trial of Intranasal Scopolamine for the Prevention of Nausea and Vomiting Induced by Motion
ST. LOUIS, June 05, 2023 (GLOBE NEWSWIRE) — Defender Pharmaceuticals, Inc. (the “Company” or “Defender”),…
Defender Pharmaceuticals Reports Positive Results from Pivotal Phase III Clinical Trial of Intranasal Scopolamine for the Prevention of Nausea and Vomiting Induced by Motion
ST. LOUIS, June 05, 2023 (GLOBE NEWSWIRE) — Defender Pharmaceuticals, Inc. (the “Company” or “Defender”),…
Janssen Announces Erdafitinib Improved Overall Survival Versus Chemotherapy in Patients with Metastatic or Unresectable Urothelial Carcinoma and Selected Fibroblast Growth Factor Receptor Gene Alterations After Prior Anti-PD-(L)1 Treatment
Confirmatory data from Cohort 1 of the Phase 3 THOR study showed greater than four-month…
Janssen Announces Erdafitinib Improved Overall Survival Versus Chemotherapy in Patients with Metastatic or Unresectable Urothelial Carcinoma and Selected Fibroblast Growth Factor Receptor Gene Alterations After Prior Anti-PD-(L)1 Treatment
Confirmatory data from Cohort 1 of the Phase 3 THOR study showed greater than four-month…
UPDATE – Cellebrite Announces Innovative Case-Closing Technology; Raising the Bar for Modern Investigations
Building on established “Collect and Review” Solutions, UFED Ultra brings new level of excellence to digital forensics…
UPDATE – Cellebrite Announces Innovative Case-Closing Technology; Raising the Bar for Modern Investigations
Building on established “Collect and Review” Solutions, UFED Ultra brings new level of excellence to digital forensics…